CD200-CD200R的不同机制在癌症治疗中诱导了不同的结果
Kang-Ling Liao1, Kenton D Watt1, Tom Protin2
1Department of Mathematics, University of Manitoba, Winnipeg, Manitoba, R3T 2N2, Canada.
Mathematical biosciences
|September 21, 2023
概括
CD200-CD200R免疫检查点在不同癌症中具有相反的作用. 数学模型揭示了驱动CD200阻断功效的独特机制,影响了组合癌症免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 计算生物学 计算生物学
背景情况:
- CD200-CD200R轴涉及瘤细胞上的细胞膜蛋白及其免疫细胞上的受体,充当免疫检查点.
- CD200-CD200R相互作用通常会抑制免疫细胞的功能,使其封锁成为潜在的癌症治疗策略.
- 然而,CD200阻塞在不同类型的癌症中表现出不同的结果,这表明了取决于背景的机制.
研究的目的:
- 探讨在瘤微环境中的不同的CD200-CD200R机制解释了不同的CD200阻塞治疗结果的假设.
- 开发和利用普通微分方程 (ODEs) 模型来模拟CD200-CD200R在黑色素瘤和胰腺管道腺癌 (PDAC) /头角状细胞癌 (HNSCC) 中的作用.
- 在不同癌症模型中评估CD200-CD200R阻断和抗PD-1免疫疗法的有效性.
主要方法:
- 构建两个不同的ODE模型:一个用于黑色素瘤 (包括CCL8抑制,调节性T细胞和M2-M1巨细胞切换),另一个用于PDAC/HNSCC (重点关注M2巨细胞两极分化和抑制活性促进).
- 使用开发的ODE模型模拟CD200-CD200R阻塞和抗PD-1组合疗法.
- 分析CD200-CD200R在不同癌症背景下对特定免疫细胞群 (M1/M2巨细胞,树突细胞,调节性T细胞) 的影响.
主要成果:
- CD200-CD200R阻断通过抑制M1巨细胞和树突细胞而不是M2巨细胞,有效地降低了黑色素瘤中的瘤负载.
- 在PDAC和HNSCC中,CD200-CD200R信号促进了瘤生长;与抗PD-1和CD200淘汰赛的联合治疗降低了瘤负载.
- 独特的ODE模型表明,CD200-CD200R信号传递的差异化机制导致组合免疫疗法产生不同的反应.
结论:
- 瘤微环境中CD200-CD200R信号传递的上下文依赖机制是CD200阻断有效性的关键决定因素.
- 数学建模为剖析复杂的免疫相互作用和预测癌症治疗结果提供了强大的工具.
- 根据CD200-CD200R等免疫检查点的特定作用量身定制组合免疫疗法,对于优化治疗策略至关重要.
关键词:
CD200-CD200R CD200-CD200R CD200-CD200R CD200-CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD200R CD2R CD2R CD2R CD2R CD2R CD2R CD2R免疫检查站检查站一个ODE模型的ODE模型.在PD-1-PD-L1中.
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K